Dermatology On-Call Data Uncover Trends in Hematology–Oncology Cutaneous Complications
Oncodermatology consults for hematological malignancy patients often uncover therapy-related skin toxicities that can derail cancer treatment. In a retrospective review of 134 acute hematology-oncology oncodermatology referrals from August 2020 to November 2022, cutaneous adverse drug eruptions led the spectrum at 22%, followed by leukemia or lymphoma cutis (13%), secondary infections (13%), and acneiform eruptions (10%)—with myeloid neoplasms showing a notably high 32% drug reaction rate. These real-world oncodermatology insights into adverse drug reactions, leukemia cutis, and acneiform eruptions underscore the evolving role of dermatology in immunosuppressed patients.
As novel hematology-oncology treatments expand, prompt dermatologic expertise will be critical to ensure accurate diagnosis, timely management, and optimal patient outcomes. Read the full paper to learn more.
J Drugs Dermatol. 2025;24(10):1018-1023. doi:10.36849/JDD.8965
Blog write-up assisted by AI
